TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.0900nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: <0.100nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.100nMAssay Description:Inhibition of human recombinant PDGFRbetaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.100nMAssay Description:Inhibition of human recombinant PDGFRbetaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: <0.100nMAssay Description:Inhibition of PDGFRalphaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.140nMAssay Description:An in vitro kinase assay was performed to evaluate the kinase suppression activity of the most promising cytotoxic candidates 4b, 4j against four dif...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.180nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.190nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of PDGFRbetaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of PDGFRbetaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of human recombinant PDGFRbetaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.240nMAssay Description:Inhibition of human recombinant PDGFRalpha in cell free system after 60 minsMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.260nMAssay Description:An in vitro kinase assay was performed to evaluate the kinase suppression activity of the most promising cytotoxic candidates 4b, 4j against four dif...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of human recombinant PDGFRbetaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of human recombinant PDGFRbetaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of PDGFRbeta phosphorylation by cell based assayMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of PDGFRbetaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.320nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of PDGFRbetaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of platelet-derived growth factor receptor beta phosphorylation in MG63 cells in the absence of plasmaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of platelet-derived growth factor receptor beta phosphorylation in MG63 cells in the absence of plasmaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of PDGFRbeta (unknown origin) after 10 mins by mobility shift assayMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of PDGFRbeta phosphorylation by cell based assayMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of human recombinant PDGFRbetaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.418nMAssay Description:Inhibition of human PDGFRalpha using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.420nMAssay Description:An in vitro kinase assay was performed to evaluate the kinase suppression activity of the most promising cytotoxic candidates 4b, 4j against four dif...More data for this Ligand-Target Pair